Fatal acute graft-versus-host disease in Sezary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation
This report describes the case of a 37-year-old man with advanced SS who received mogamulizumab therapy followed by allo-HCT from an HLA-identical sibling donor. The patient developed severe gastrointestinal acute GvHD, which was treated with steroids and infliximab. However, the condition rapidly progressed to severe intestinal symptoms and life-threatening haemorrhagic shock, ultimately resulting in the patient's death. This case highlights a potential link between mogamulizumab and severe acute GvHD promoted by drug-induced suppression of regulatory T cells. Further research is required to fully understand the interaction between mogamulizumab and allo-HCT and to determine whether it is an optimal approach as a bridge to transplant therapy. This paradigmatic case suggests the need of personalizing transplant strategies by selecting appropriate conditioning therapy and GvHD prophylaxis to minimize potential toxicity.PMID:38718540 | DOI:10.1016/j.retram.2024.103452
Source: Cell Research - Category: Cytology Authors: Gentiana Elena Trotta Giulia Ciangola Ilaria Cerroni Valeria Mezzanotte Andrea Nunzi Lucia Anemona Luca Savino Gottardo De Angelis Benedetta Mariotti Fabrizio Bonanni Elisa Meddi Annagiulia Zizzari Vito Mario Rapisarda Ilaria Mangione Antonio Bruno Maria Source Type: research
More News: Cytology | Gastroenterology | Lymphoma | Remicade | Sezary Syndrome | T-cell Lymphoma | Toxicology | Transplants